Amivantamab Combinations for Non-Small Cell Lung Cancer
(COPERNICUS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that any side effects from previous cancer treatments must be resolved before starting the trial.
Is Amivantamab safe for humans?
What makes the drug amivantamab unique for treating non-small cell lung cancer?
Amivantamab is unique because it is a bispecific antibody that targets both EGFR and MET, specifically designed for non-small cell lung cancer with EGFR Exon 20 insertion mutations, especially after other treatments like platinum-based chemotherapy have failed. This dual-targeting approach is different from many other treatments that typically focus on a single target.12346
What data supports the effectiveness of the drug Amivantamab for treating non-small cell lung cancer?
Amivantamab has been approved for treating non-small cell lung cancer (NSCLC) with specific genetic mutations after other treatments have failed, showing it can be effective in these cases. It has shown safety and antitumor activity when combined with chemotherapy drugs like carboplatin and pemetrexed.12345
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
This trial is for adults with advanced or metastatic non-small cell lung cancer (NSCLC) that can't be treated with surgery. Participants must have specific EGFR mutations, at least one measurable lesion not previously irradiated, and should have recovered from previous cancer treatments to a certain extent. They need to be in good physical condition as measured by ECOG standards.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Amivantamab in combination with Lazertinib or chemotherapy in cycles until disease progression or other criteria are met
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Amivantamab
- Chemotherapy: Carboplatin
- Chemotherapy: Pemetrexed
Amivantamab is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University